FDA Approves Sun Pharma’s Yonsa for Treatment of Metastatic Castration-Resistant Prostate Cancer

09:31 EDT 24 May 2018 | Speciality Pharma Journal

MUMBAI & PRINCETON, N.J. & KING OF PRUSSIA, Pa.–(BUSINESS WIRE)–Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) and Churchill Pharmaceuticals, LLC. (Churchill) today announced that one of Sun Pharma’s wholly owned subsidiary companies has received approval from the U.S. Food and …

More From BioPortfolio on "FDA Approves Sun Pharma’s Yonsa for Treatment of Metastatic Castration-Resistant Prostate Cancer"